ATE422368T1 - Multikomponenten impfstoffe gegen staphylococcus aureus - Google Patents

Multikomponenten impfstoffe gegen staphylococcus aureus

Info

Publication number
ATE422368T1
ATE422368T1 AT99942533T AT99942533T ATE422368T1 AT E422368 T1 ATE422368 T1 AT E422368T1 AT 99942533 T AT99942533 T AT 99942533T AT 99942533 T AT99942533 T AT 99942533T AT E422368 T1 ATE422368 T1 AT E422368T1
Authority
AT
Austria
Prior art keywords
proteins
fragments
fragment
protein
bacterial
Prior art date
Application number
AT99942533T
Other languages
English (en)
Inventor
Joseph Patti
Timothy J Foster
Magnus Hook
Original Assignee
Inhibitex Inc
Texas A & M Univ Sys
Trinity College Dublin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inhibitex Inc, Texas A & M Univ Sys, Trinity College Dublin filed Critical Inhibitex Inc
Application granted granted Critical
Publication of ATE422368T1 publication Critical patent/ATE422368T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1275—Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Gram-positive bacteria
    • C07K16/1271—Micrococcaceae (F); Staphylococcaceae (F), e.g. Staphylococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT99942533T 1998-08-31 1999-08-31 Multikomponenten impfstoffe gegen staphylococcus aureus ATE422368T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9843998P 1998-08-31 1998-08-31

Publications (1)

Publication Number Publication Date
ATE422368T1 true ATE422368T1 (de) 2009-02-15

Family

ID=22269290

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99942533T ATE422368T1 (de) 1998-08-31 1999-08-31 Multikomponenten impfstoffe gegen staphylococcus aureus

Country Status (13)

Country Link
EP (1) EP1109577B1 (de)
JP (2) JP2002523473A (de)
KR (1) KR100644953B1 (de)
CN (1) CN1314450C (de)
AT (1) ATE422368T1 (de)
AU (1) AU771426B2 (de)
BR (1) BR9913340A (de)
CA (2) CA2340304C (de)
DE (1) DE69940404D1 (de)
ES (1) ES2322409T3 (de)
IL (1) IL141639A (de)
MX (1) MXPA01002119A (de)
WO (1) WO2000012131A1 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1117772B1 (de) * 1998-08-31 2012-10-24 The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin Polypeptide und polynukleotide aus coagulase-negativen staphylokokken
WO2000012132A1 (en) * 1998-08-31 2000-03-09 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
US6692739B1 (en) 1998-08-31 2004-02-17 Inhibitex, Inc. Staphylococcal immunotherapeutics via donor selection and donor stimulation
GB0014907D0 (en) * 2000-06-20 2000-08-09 Univ Sheffield Antigenic polypeptides
JP2004512040A (ja) * 2000-10-20 2004-04-22 インヒビテックス　インコーポレーテッド Ｍａｐタンパク質に対するモノクローナル抗体、および感染を処置または予防することにおける使用方法
US20040006209A1 (en) * 2002-03-05 2004-01-08 Patti Joseph M. Monoclonal and polyclonal antibodies recognizing coagulase-negative staphylococcal proteins
US9296795B2 (en) * 2003-03-07 2016-03-29 Wyeth Holdings, Llc. Polysaccharide-staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections
WO2004094600A2 (en) * 2003-04-16 2004-11-04 The Texas A & M University System Staphylococcus aureus efb protein and c3 binding region which inhibit complement activation
US20070026011A1 (en) * 2003-05-29 2007-02-01 Inhibitex, Inc. Sdr proteins from staphylococcus capitis and their use in preventing and treating infections
JP2008513406A (ja) * 2004-09-22 2008-05-01 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム 免疫原性組成物
JP4088328B2 (ja) * 2004-12-28 2008-05-21 第一化学薬品株式会社 抗ヒト可溶性フィブリンモノクローナル抗体及び当該抗体を用いる免疫学的測定方法
GB0526038D0 (en) 2005-12-21 2006-02-01 Glaxosmithkline Biolog Sa Immunogenic composition
AU2007281934B2 (en) * 2006-01-18 2012-11-15 University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
EP1998802A2 (de) * 2006-03-30 2008-12-10 GlaxoSmithKline Biologicals S.A. Immunogene zusammensetzung
MX2010000864A (es) * 2007-07-23 2010-04-30 Vaccine Res Internat Plc Vacuna de celulas enteras estafilococcicas inactivadas.
AU2008292897B2 (en) 2007-08-31 2015-01-22 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
EA018068B1 (ru) 2008-03-03 2013-05-30 Айрм Ллк Соединения и композиции в качестве модуляторов активности tlr
US8758765B2 (en) 2008-07-29 2014-06-24 The University Of Chicago Compositions and methods related to Staphylococcal bacterium proteins
PT3281947T (pt) 2009-04-03 2020-05-07 Univ Chicago Composições e métodos relacionados com variantes da proteína a (spa)
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
BRPI1015567A2 (pt) 2009-06-22 2021-08-31 Wyeth Llc Composições imunogênicas de antígenos de staphylococcus aureus
TWI505834B (zh) 2009-06-22 2015-11-01 Wyeth Llc 組合物及製備金黃色葡萄球菌血清型５及８莢膜多醣結合物之免疫原性組合物之方法
BR112012000953A8 (pt) * 2009-07-15 2017-12-26 Aimm Therapeutics Bv anticorpos de ligação a bactérias gram-positivas, sequência de ácido nucleico,seus usos e seu método de produção, células isolada ou produtora de anticorpo isolado ou recombinante, composições, e método de isolamento de bactérias
SG178954A1 (en) 2009-09-02 2012-04-27 Novartis Ag Immunogenic compositions including tlr activity modulators
TWI445708B (zh) 2009-09-02 2014-07-21 Irm Llc 作為ｔｌｒ活性調節劑之化合物及組合物
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
AU2010339921B2 (en) 2009-12-15 2016-08-11 Glaxosmithkline Biologicals S.A. Homogeneous suspension of immunopotentiating compounds and uses thereof
AU2011232421B2 (en) 2010-03-23 2015-08-13 Novartis Ag Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etc.
EP2588120B1 (de) 2010-07-02 2017-11-15 The University of Chicago Zusammensetzungen und verfahren bezüglich protein-a (spa)-varianten
US9192661B2 (en) 2010-07-06 2015-11-24 Novartis Ag Delivery of self-replicating RNA using biodegradable polymer particles
RU2570730C2 (ru) * 2010-12-22 2015-12-10 УАЙТ ЭлЭлСи Стабильные иммуногенные композиции антигенов staphylococcus aureus
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
KR20150024315A (ko) * 2012-05-07 2015-03-06 재단법인 목암생명공학연구소 포도상구균 감염 예방용 백신 조성물
TR201807340T4 (tr) 2013-02-01 2018-06-21 Glaxosmithkline Biologicals Sa Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi.
EP3229833A1 (de) * 2014-12-10 2017-10-18 GlaxoSmithKline Biologicals SA Behandlungsverfahren
CN107007832A (zh) * 2016-01-28 2017-08-04 中创云牧科技咨询(北京)股份有限公司 一种ClfA-A靶位的金黄色葡萄球菌奶牛乳房炎疫苗的制备方法
BR112020016314A2 (pt) 2018-02-12 2020-12-15 Inimmune Corporation Compostos ou um sais farmaceuticamente aceitáveis, composição farmacêutica, kit, e, métodos para elicitar, intensificar ou modificar uma resposta imunológica, para tratar, prevenir ou reduzir a suscetibilidade a câncer, para tratar, prevenir ou reduzir a suscetibilidade a uma doença infecciosa, para tratar, prevenir ou reduzir a suscetibilidade a uma alergia, para tratar, prevenir ou reduzir a suscetibilidade a uma afecção autoimune, para tratar, prevenir ou reduzir a suscetibilidade em um sujeito à infecção bacteriana, viral, priônica, autoimunidade, câncer ou alergia, para tratar, prevenir ou reduzir a suscetibilidade à autoimunidade, alergia, reperfusão de isquemia ou sepse, para tratar, prevenir ou reduzir a gravidade de ataques epiléticos e para tratar, prevenir ou reduzir a suscetibilidade a doenças oculares como degeneração macular, hipertensão ocular e infecção ocular
BR112021022902A2 (pt) 2019-05-14 2022-01-25 Univ Chicago Métodos e composições que compreendem variantes de proteína a staphylococcus (spa)
WO2021051136A1 (en) 2019-09-13 2021-03-18 The University Of Chicago Methods and compositions for treating staphylococcal infections
KR102528412B1 (ko) * 2020-09-08 2023-05-04 클립스비엔씨 주식회사 신규한 포도상구균 감염 질환의 예방 또는 치료용 조성물
EP4240843A1 (de) 2020-11-04 2023-09-13 Eligo Bioscience Rekombinante phagen von cutibacterium acnes, herstellungsverfahren und verwendungen davon

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189015A (en) * 1984-05-30 1993-02-23 Alfa-Laval Agri International Ab Method for prophylactic treatment of the colonization of a Staphylococcus aureus bacterial strain by bacterial cell surface protein with fibronectin and fibrinogen binding ability
SE454403B (sv) * 1984-05-30 1988-05-02 Alfa Laval Agri Int Anvendning av ett cellyteprotein med fibronektin-, fibrinogen-, kollagen-, och/eller lamininbindande egenskaper vid framstellning av sarbehandlingsmedel
US5730978A (en) * 1989-09-01 1998-03-24 Fred Hutchinson Cancer Research Center Inhibition of lymphocyte adherence with α4β1-specific antibodies
US5440014A (en) * 1990-08-10 1995-08-08 H+E,Uml/Oo/ K; Magnus Fibronectin binding peptide
US5851794A (en) * 1990-10-22 1998-12-22 Alfa Laval Ab Collagen binding protein as well as its preparation
US5648240A (en) * 1994-05-24 1997-07-15 Texas A&M University MHC II analog from Staphylococcus aureus
EP0950068B1 (de) * 1996-05-16 2005-11-09 THE TEXAS A&M UNIVERSITY SYSTEM Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
SE9602496D0 (sv) * 1996-06-20 1996-06-20 Bengt Guss Method and means for producing a fibrinogen binding protein and its use in biotechnology
ATE439862T1 (de) * 1997-01-21 2009-09-15 Texas A & M Univ Sys Fibronektinbindungsprotein abgeleitete peptide, die nicht an fibronektin binden, antikírper dagegen und therapeutische anwendung
EP1034277B1 (de) * 1997-11-26 2012-06-27 Inhibitex, Inc. Extrazelluläre Matrix-bindende Proteine von Staphylococcus aureus

Also Published As

Publication number Publication date
KR20010085745A (ko) 2001-09-07
CA2777661A1 (en) 2000-03-09
WO2000012131A1 (en) 2000-03-09
CN1314450C (zh) 2007-05-09
JP2011168607A (ja) 2011-09-01
EP1109577A1 (de) 2001-06-27
EP1109577A4 (de) 2002-03-13
CA2340304C (en) 2012-12-04
DE69940404D1 (de) 2009-03-26
JP2002523473A (ja) 2002-07-30
IL141639A0 (en) 2002-03-10
CN1317976A (zh) 2001-10-17
ES2322409T3 (es) 2009-06-19
AU771426B2 (en) 2004-03-18
BR9913340A (pt) 2001-11-06
KR100644953B1 (ko) 2006-11-10
JP5460642B2 (ja) 2014-04-02
EP1109577B1 (de) 2009-02-11
MXPA01002119A (es) 2003-03-27
CA2777661C (en) 2014-10-21
AU5588999A (en) 2000-03-21
CA2340304A1 (en) 2000-03-09
IL141639A (en) 2005-12-18

Similar Documents

Publication Publication Date Title
ATE422368T1 (de) Multikomponenten impfstoffe gegen staphylococcus aureus
WO2002072600A3 (en) Monoclonal antibodies to the clfa protein and method of use in treating or preventing infections
WO1999027109A3 (en) EXTRACELLULAR MATRIX-BINDING PROTEINS FROM $i(STAPHYLOCOCCUS AUREUS)
ATE309271T1 (de) Zusammensetzungen von kollagenbindungsprotein und verfahren zur deren verwendungen
DK0759774T3 (da) Fremgangsmåde til behandling af gram-negativ bakteriel infektion ved indgivelse af baktericidt/permeabilitet-forøgende (BPI) proteinprodukt og antibiotikum
RU94046367A (ru) Днк, хозяйская клетка, способ получения белка, белок, фармацевтический препарат, антитело, применение антитела
AU2002305450A1 (en) Proteomimetic compounds and methods
DE60218998D1 (de) Auf Bläschen basierendes Impfstoff gegen Chlamydia
WO2001052791A3 (en) Complexes of peptide-binding fragments of heat shock proteins and their use as immunotherapeutic agents
AU5751000A (en) Groups of borrelia burgdorferi and borrelia afzelii that cause lyme disease in humans
EP1988099A3 (de) Insektizide Proteine von Bacillus thuringiensis
CY1106234T1 (el) Συνθεσεις για τη θepαπεια μολυνσεων staphylococcus aureus
DE69732709D1 (de) Expressionsblockierung von virulenten faktoren in s. aureus
WO1999001473A3 (en) Anti-bacterial methods and materials
DE69914911D1 (de) Pharmazeutische präparate zur bekämpfung oder prophylaxe von mikroorganismen infizierten oberflächen
BR9710899A (pt) Composição compreendendo mupirocin e clorohexidina.
ATE266091T1 (de) Rekombinante phagen
PT946730E (pt) Mutantes de toxina estreptococica c e metodos de utilizacao
GB9723945D0 (en) Tissue cement
CY1107038T1 (el) Μεθοδος θεραπειας βακτηριακων λοιμωξεων με χρηση της γεμιφλοξασινης ή ενος αλατος αυτης και ενος αντιβιοτικου β-λακταμης
WO2002057281A3 (en) Aminoglycosides as antibiotics
DE60024977D1 (de) Klonierung und expression von haemophilus somnus transferrin-bindenden proteinen
AU2002224437A1 (en) Monoclonal antibodies to the map protein and method of use in treating or preventing infections
WO2005010167A3 (en) Antibodies to the fbsa protein of streptococcus agalactiae and their use in treating or preventing infections
WO2002090383A3 (en) M. catarrhalis antigens

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties